Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who have been diagnosed with non-cystic fibrosis bronchiectasis (a lung condition causing widened, damaged airways — but not caused by cystic fibrosis), confirmed by a clinical assessment and a detailed CT scan of the chest
- People whose condition is currently stable or being monitored as part of routine care, and who are being assessed for how severe their condition is
- People who are attending outpatient clinics, hospital wards, or respiratory follow-up services at Assiut University Hospitals during the time the study is enrolling participants
- People who are able to take part in a structured assessment of their bronchiectasis severity using a specific framework called the BASE framework
- People who are able to complete the routine clinical tests required by the study, including breathing tests, imaging, oxygen level checks, and blood tests
- People who are able to attend follow-up appointments over 12 months to track their condition and any flare-ups
- People who have given written consent to take part, or whose legal representative has done so on their behalf
Who may not be able to join:
- People whose bronchiectasis is caused by cystic fibrosis
- People whose main lung diagnosis is advanced scarring lung disease that has caused the airways to widen as a side effect (confirm with trial site)
- People who have active tuberculosis (TB) of the lungs at the time of enrolment
- People who have an active lung infection caused by a type of bacteria called nontuberculous mycobacteria, which is currently being treated
- People who have an active cancer or a serious non-lung illness that is expected to prevent them from completing 12 months of follow-up
- People who have a severe, life-threatening illness at the time of enrolment that would make it unsafe to participate
- People who have recently had major chest surgery or a serious chest injury that would interfere with the initial assessments
- People who are unable to complete the required tests and assessments at the start of the study
- People who are unable or unwilling to attend follow-up appointments over the 12-month period
- People who do not wish to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ahmad M Shaddad, MD, Assiut University
Phone: +201111171930
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Twelve-Month Bronchiectasis Exacerbation Risk Predicted by the BASE Prognostic Model (BASE-P)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.